Biotin Interference with Laboratory Tests
Biotin doses of 5 mg/day or higher can interfere with laboratory immunoassays, and patients should discontinue biotin for at least 3 days (72 hours) before testing to avoid false results. 1
Critical Dosage Thresholds
The interference threshold varies by assay type and manufacturer, but the evidence establishes clear parameters:
- ≥5 mg daily: This is the clinically significant threshold where biotin must be stopped at least 3 days prior to testing 1
- 10 mg daily: Demonstrated significant interference with TSH, free T4, total T3, and thyroglobulin assays in prospective studies 2
- 50-250 ng/mL serum levels: Begin causing measurable interference in various immunoassays 3
- >500 ng/mL serum levels: Cause >20% changes in assay values, producing false-low results for thyroglobulin and AFP, and false-high results for anti-thyroglobulin and free T4 4
- 100-300 mg daily: Poses significant problems across multiple immunoassay platforms 5, 6
Mechanism and Affected Assays
Biotin interferes specifically with immunoassays using streptavidin-biotin chemistry. The interference pattern depends on assay format:
- Competitive assays (e.g., free T3, free T4): Biotin causes falsely elevated results (positive interference)
- Sandwich assays (e.g., TSH, troponin, cardiac markers): Biotin causes falsely decreased results (negative interference) 7
This can create a misleading laboratory picture mimicking Graves' disease—with high T4/T3, low TSH, and detectable TSH receptor antibodies—in clinically euthyroid patients 8, 9.
Platform-Specific Considerations
Roche Cobas systems show particular vulnerability to biotin interference, with older reagents affected at lower concentrations. Newer Elecsys reagents tolerate 1000-3000 ng/mL depending on the specific test 4. Abbott systems demonstrate greater resilience to biotin interference compared to Roche platforms 4.
Siemens IMMULITE 2000 shows false-low thyroglobulin levels with biotin exposure 2.
Timing of Maximum Interference
Peak interference occurs 2 hours after biotin ingestion, both on initial exposure and after chronic supplementation 2. Given biotin's short half-life, the standard recommendation is cessation for 48-72 hours before testing 10, 5.
High-Risk Patient Populations
Certain groups demonstrate significantly elevated biotin levels requiring heightened vigilance:
- Hemodialysis patients (mean 3.282 ng/mL)
- ICU patients (mean 3.212 ng/mL)
- Patients receiving biotin for metabolic diseases (doses up to 200 mg/day IV) 11
- Multiple sclerosis patients on high-dose biotin therapy
These patients may require biotin depletion methods or alternative assay platforms 4.
Clinical Pitfalls
The most dangerous scenario involves misdiagnosis of Graves' disease in biotin users, potentially leading to inappropriate antithyroid therapy 8. Similarly, false-low troponin results could delay critical cardiac interventions 12, 13.
For patients with suspected biotinidase deficiency or those requiring urgent testing, biotin cessation may not be feasible. In these cases, use assays not based on streptavidin-biotin chemistry or employ biotin depletion techniques 1, 4.
Practical Management Algorithm
- Screen all patients for biotin supplement use before ordering immunoassays
- If biotin dose ≥5 mg/day: Stop for minimum 3 days before testing 1
- If biotin dose 10-300 mg/day: Stop for 48-72 hours minimum 10, 5
- Emergency situations: Use LC-MS/MS methods or non-biotin-based assays when available 2
- Discordant results: When laboratory values conflict with clinical presentation, specifically inquire about over-the-counter biotin supplements 13
The FDA has stipulated that manufacturers must investigate biotin interference up to 3510 ng/mL (14,367 nM) 6, though this threshold may not capture all clinically relevant interference patterns.